| vasoactive intestinal peptide receptor 1 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | VIPR1 | ||||||
| Alt. symbols | RDC1, HVR1, VAPC1 | ||||||
| NCBI gene | 7433 | ||||||
| HGNC | 12694 | ||||||
| OMIM | 192321 | ||||||
| RefSeq | NM_004624 | ||||||
| UniProt | P32241 | ||||||
| Other data | |||||||
| Locus | Chr. 3 p22 | ||||||
| |||||||
| vasoactive intestinal peptide receptor 2 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | VIPR2 | ||||||
| Alt. symbols | VPAC2 | ||||||
| NCBI gene | 7434 | ||||||
| HGNC | 12695 | ||||||
| OMIM | 601970 | ||||||
| RefSeq | NM_003382 | ||||||
| UniProt | P41587 | ||||||
| Other data | |||||||
| Locus | Chr. 7 q36.3 | ||||||
| |||||||
| adenylate cyclase activating polypeptide 1 (pituitary) receptor type I | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | ADCYAP1R1 | ||||||
| Alt. symbols | PACAPR | ||||||
| NCBI gene | 117 | ||||||
| HGNC | 242 | ||||||
| OMIM | 102981 | ||||||
| RefSeq | NM_001118 | ||||||
| UniProt | P41586 | ||||||
| Other data | |||||||
| Locus | Chr. 7 p14 | ||||||
| |||||||
There are two known receptors for the vasoactive intestinal peptide (VIP) termed VPAC1 and VPAC2.[1][2] These receptors bind both VIP and pituitary adenylate cyclase-activating polypeptide (PACAP) to some degree. Both receptors are members of the 7 transmembrane G protein-coupled receptor family.
VPAC1 is distributed widely in the CNS, liver, lung, intestine and T-lymphocytes.
VPAC2 is found in the CNS, pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach.
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors are activated by the endogenous peptides VIP, PACAP-38, PACAP-27, peptide histidine isoleucineamide (PHI), peptide histidine methionineamide (PHM) and peptide histidine valine (PHV). “PACAP type II receptors” (VPAC1 and VPAC2 receptors) display comparable affinity for PACAP and VIP, whereas PACAP-27 and PACAP-38 are >100 fold more potent than VIP as agonists of most isoforms of the PAC1 receptor.[3]
|
| |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
|
| |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G protein-coupled receptor |
| ||||||||||||
| Type I cytokine receptor |
| ||||||||||||
| Enzyme-linked receptor |
| ||||||||||||
| Other |
| ||||||||||||
 | This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it. |
